Columbia Labs Slams Investor Suit Over Rejected Drug

Law360, New York (August 12, 2013, 3:55 PM EDT) -- Columbia Laboratories Inc. fired back Friday in New Jersey federal court against consolidated investor claims that the company and its executives inflated its stock by talking up its premature-birth-preventing drug Prochieve despite allegedly knowing regulators would not approve it, saying the claims lack support.  

In a motion to dismiss filed in New Jersey federal court, the Boston-based pharmaceutical company argued that the investors had not sufficiently supported their claims that the company knowingly withheld information that the U.S. Food and Drug Administration was not going...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

WRIGHT v. COLUMBIA LABORATORIES, INC. et al


Case Number

2:12-cv-00614

Court

New Jersey

Nature of Suit

Securities/Commodities

Judge

Faith S. Hochberg

Date Filed

January 31, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.